Lexicon Pharmaceuticals, Inc. (LXRX) financial statements (2021 and earlier)

Company profile

Business Address 8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS, TX 77381
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments272160311347521339129
Cash and cash equivalents3680624720313737
Short-term investments2368024930031820292
Receivables57657111
Inventory, net of allowances, customer advances and progress billings452   
Inventory452    
Other current assets53441055
Other undisclosed current assets     24 
Total current assets:338173322358532369135
Noncurrent Assets
Property, plant and equipment1416181921141
Intangible assets, net (including goodwill)64959698989845
Goodwill45454545454545
Intangible assets, net (excluding goodwill)205052535353 
Regulated entity, other noncurrent assets     3 
Other noncurrent assets2000330
Other undisclosed noncurrent assets     (3)54
Total noncurrent assets:80111115118122102140
TOTAL ASSETS:418284437476655471274
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities54327085442317
Accounts payable12185853201310
Accrued liabilities4214123225108
Debt11114162202
Deferred revenue and credits40637620
Other undisclosed current liabilities 3     
Total current liabilities:65371241651234519
Noncurrent Liabilities
Long-term debt and lease obligation, including:1244232851048820
Long-term debt, excluding current maturities234244232851048820
Other undisclosed long-term debt and lease obligation(233)      
Liabilities, other than long-term debt1629681425565
Deferred revenue and credits22491091313
Deferred tax liabilities, net6619191919
Other liabilities1001142432
Other undisclosed noncurrent liabilities23324     
Total noncurrent liabilities:23527426015424614285
Total liabilities:301311384318369187104
Stockholders' equity
Stockholders' equity attributable to parent117(26)52157286284170
Common stock0000011
Treasury stock, value(4)(3)(2)(3)(3)(2)(2)
Additional paid in capital1,4621,4481,4361,4111,3981,3901,175
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)(0)0
Accumulated deficit(1,341)(1,472)(1,381)(1,250)(1,109)(1,104)(1,004)
Total stockholders' equity:117(26)52157286284170
TOTAL LIABILITIES AND EQUITY:418284437476655471274

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues322639083130232
Revenue, net9083130232
Cost of revenue
(Cost of Goods and Services Sold)
(3)(2)(2)    
Gross profit:319618883130232
Operating expenses(181)(166)(227)(220)(129)(123)(105)
Other undisclosed operating income322    
Operating income (loss):141(103)(137)(137)1(100)(102)
Nonoperating income3422120
Investment income, nonoperating      0
Other nonoperating income3422120
Interest and debt expense(21)(21)(7)(7)(7)(2)(2)
Income (loss) from continuing operations before income taxes:124(121)(142)(141)(5)(100)(104)
Income tax benefit6 13  0 
Income (loss) before gain (loss) on sale of properties:130(121)(129)(141)(5)(100)(104)
Other undisclosed net income0      
Net income (loss) available to common stockholders, basic:130(121)(129)(141)(5)(100)(104)
Dilutive securities, effect on basic earnings per share135      
Net income (loss) available to common stockholders, diluted:265(121)(129)(141)(5)(100)(104)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss):130(121)(129)(141)(5)(100)(104)
Comprehensive income (loss):130(121)(129)(141)(5)(100)(104)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)0(0)(0)(0)
Comprehensive income (loss), net of tax, attributable to parent:130(120)(129)(141)(5)(100)(104)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: